Introduction and Objective: Several GLP-1 drugs are FDA approved for type 2 diabetes (T2D) or obesity. The 2024 ADA standards of care highlight that for individuals with T2D and obesity/overweight, GLP-1 therapy is preferred. While many adults with T1D are overweight/obese, GLP-1 use in this population is not well characterized. Data from the T1D Exchange Online Registry was leveraged to assess self-reported GLP-1 use by demographic and clinical characteristics.

Methods: Registry participants complete questionnaires annually. This analysis includes T1D adults who completed a questionnaire in 2023.

Results: Among 8,053 adults, 470 (5.8%) reported using a GLP-1, % using GLP-1 by characteristics are shown in the Table. Median HbA1c was similar in those using (6.6%) and not using (6.5%) GLP-1. GLP-1 use was more common in adults with obesity and cardiovascular disease and less common among those with severe hypoglycemia. Among those with known GLP-1 type (n=109), 67% used semaglutide, 16% tirzepatide, 10% dulaglutide, 6% liraglutide and 1% exenatide.

Conclusion: GLP-1 use in this cohort of adults with T1D is low despite increasing prevalence of obesity. With increased focus on treatment of obesity, trends of GLP-1 use in those with T1D may change over time. Considering the benefits of these agents, further prospective research focused on this population is needed.

graphic
View largeDownload slide
Disclosure

K. Miller: Consultant; Dexcom, Inc. Research Support; Dexcom, Inc. H. Nguyen: None. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. Y.C. Kudva: Research Support; Dexcom, Inc. Other Relationship; Tandem Diabetes Care, Inc., Medtronic. A.L. Carlson: Research Support; Medtronic, Insulet Corporation, Tandem Diabetes Care, Inc., Eli Lilly and Company, Sanofi. Other Relationship; Novo Nordisk. Advisory Panel; MannKind Corporation. Research Support; Dexcom, Inc. N. Chaytor: None. D. DeSalvo: Advisory Panel; Insulet Corporation. Consultant; Dexcom, Inc. M.E. Hilliard: None. B.E. Marks: Research Support; Tandem Diabetes Care, Inc., Dexcom, Inc., Medtronic, Digostics. Advisory Panel; International Society for Pediatric and Adolescent Diabetes, American Diabetes Association, T1D Exchange. Board Member; Juvenile Diabetes Research Foundation (JDRF). M.L. Litchman: Research Support; American Diabetes Association, Association of Diabetes Care & Education Specialists, Dexcom, Inc. Other Relationship; Association of Diabetes Care & Education Specialists. Research Support; National Institutes of Health. C. Berget: Speaker's Bureau; Dexcom, Inc., Insulet Corporation, embecta. W. Wolf: None.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust (G-2103-05086)

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.